Spots Global Cancer Trial Database for cytosar
Every month we try and update this database with for cytosar cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) | NCT01444742 | Leukemia Myeloproliferat... | Clofarabine Cytarabine | 18 Years - | M.D. Anderson Cancer Center | |
| A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT02532192 | Lymphoma | Belinostat Rituximab Cisplatin Cytarabine Dexamethasone Ciprofloxacin Fluconazole | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide | NCT00850304 | Leukemia, Myelo... | Cytosar Arsenic trioxid... | 60 Years - | Tehran University of Medical Sciences | |
| Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT01019317 | Leukemia AML MDS CML | Cytarabine Fludarabine | 12 Years - | M.D. Anderson Cancer Center | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide | NCT00850304 | Leukemia, Myelo... | Cytosar Arsenic trioxid... | 60 Years - | Tehran University of Medical Sciences | |
| LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02652871 | Leukemia | LY2510924 Idarubicin Cytarabine | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies | NCT00472056 | Lymphoma | Carmustine Etoposide Cytarabine Melphalan Rituximab | - 80 Years | M.D. Anderson Cancer Center | |
| E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes | NCT01692197 | Leukemia | E7070 Idarubicin Cytarabine Dexamethasone | 18 Years - | M.D. Anderson Cancer Center | |
| Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation | NCT00591630 | Diffuse Large C... Lymphoma | Zevalin Carmustine Etoposide Cytarabine Melphalan Rituximab Stem Cell Trans... | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | NCT01272245 | Leukemia | Omacetaxine Cytarabine | 60 Years - | M.D. Anderson Cancer Center | |
| Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia | NCT01794702 | Leukemia | Decitabine Idarubicin Cytarabine Clofarabine | 18 Years - 64 Years | M.D. Anderson Cancer Center | |
| Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | NCT01538472 | Lymphoma | Y Zevalin In Zevalin Rituxan BCNU VP -16 Ara-C Melphalan Stem Cell Infus... G-CSF | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction | NCT01025154 | Acute Myeloid L... | Clofarabine Idarubicin Cytarabine | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | NCT01538472 | Lymphoma | Y Zevalin In Zevalin Rituxan BCNU VP -16 Ara-C Melphalan Stem Cell Infus... G-CSF | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide | NCT00850304 | Leukemia, Myelo... | Cytosar Arsenic trioxid... | 60 Years - | Tehran University of Medical Sciences | |
| Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome | NCT01289457 | Leukemia | Clofarabine Idarubicin Cytarabine Fludarabine | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL | NCT00452374 | Leukemia | Cytarabine Fludarabine Oxaliplatin Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger | NCT00290498 | Lymphoma | Rituximab Cyclophosphamid... Doxorubicin Vincristine Dexamethasone Methotrexate Cytarabine Prednisone | 16 Years - 60 Years | M.D. Anderson Cancer Center | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | NCT02464657 | Leukemia Acute Myeloid L... Myelodysplastic... | Nivolumab Idarubicin Cytarabine Solu-medrol Dexamethasone | 18 Years - | M.D. Anderson Cancer Center | |
| Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) | NCT02441803 | Leukemia | Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | NCT01515527 | Leukemia | Cladribine Cytarabine Decitabine | 60 Years - | M.D. Anderson Cancer Center | |
| Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients | NCT00382590 | Acute Myelogeno... Myelodysplastic... Leukemia | 5-Azacytidine Ara-C Valproic Acid (... | 60 Years - | M.D. Anderson Cancer Center | |
| Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide | NCT00850304 | Leukemia, Myelo... | Cytosar Arsenic trioxid... | 60 Years - | Tehran University of Medical Sciences | |
| LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02652871 | Leukemia | LY2510924 Idarubicin Cytarabine | 18 Years - 70 Years | M.D. Anderson Cancer Center | |
| Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | NCT02419469 | Leukemia Precursor-B Acu... Lymphoblastic L... Lymphoma | Cytarabine Daunorubicin Vincristine Prednisone PEG asparaginas... Ofatumumab Rituximab Methotrexate Cyclophosphamid... Mercaptopurine Doxorubicin Dexamethasone a... Thioguanine | 12 Years - 30 Years | M.D. Anderson Cancer Center | |
| Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome | NCT01289457 | Leukemia | Clofarabine Idarubicin Cytarabine Fludarabine | 18 Years - 60 Years | M.D. Anderson Cancer Center | |
| Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | NCT02419469 | Leukemia Precursor-B Acu... Lymphoblastic L... Lymphoma | Cytarabine Daunorubicin Vincristine Prednisone PEG asparaginas... Ofatumumab Rituximab Methotrexate Cyclophosphamid... Mercaptopurine Doxorubicin Dexamethasone a... Thioguanine | 12 Years - 30 Years | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
